Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?
| Autor: | Vergote, Ignace, ray coquard, isabelle, Lorusso, Domenica, OAKNIN, ANA, Cibula, David, Van Gorp, Toon |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Vergote I, Van Gorp T] Department of Gynecology and Obstetrics, Gynecologic Oncology, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium, Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, Belgium, European Union. [Ray-Coquard I] Medical Oncology Department, Centre Léon Bérard and University Claude Bernard Lyon 1, GINECO, Lyon, France. [Lorusso D] Gynecologic Oncology Unit, Catholic University of Sacred Heart and Fondazione Policlinico Gemelli IRCCS, Rome, Italy. [Oaknin A] Gynecologic Cancer Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Cibula D] Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. Central and Eastern European Gynecologic Oncology Group (CEEGOG), Prague, Czech Republic, Vall d'Hebron Barcelona Hospital Campus |
| Rok vydání: | 2023 |
| Předmět: |
Pharmacology
Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] aminoácidos péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados [COMPUESTOS QUÍMICOS Y DROGAS] Amino Acids Peptides and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates [CHEMICALS AND DRUGS] General Medicine Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms Female::Uterine Neoplasms::Uterine Cervical Neoplasms [DISEASES] Other subheadings::Other subheadings::/drug therapy [Other subheadings] Coll uterí - Càncer - Tractament Farmàcia - Investigació Pharmaceutical Preparations::Drugs Investigational [CHEMICALS AND DRUGS] preparados farmacéuticos::fármacos en investigación [COMPUESTOS QUÍMICOS Y DROGAS] Pharmacology (medical) Immunoglobulines neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales femeninos::neoplasias uterinas::neoplasias del cuello uterino [ENFERMEDADES] |
| Zdroj: | Scientia |
| ISSN: | 1744-7658 1354-3784 |
| DOI: | 10.1080/13543784.2023.2179483 |
| Popis: | Recurrent cervical cancer; Combination therapy; Immunotherapy Cáncer cervical recurrente; Terapia de combinación; Inmunoterapia Càncer cervical recurrent; Teràpia combinada; Immunoteràpia Introduction: Recurrent or primary advanced metastatic cervical cancer (R/M CC) has a poor prognosis with a 5-year-survival rate of 16.5%, demanding novel and improved therapies for the treatment of these patients. The first-line standard of care for R/M CC now benefits from the addition of the immune checkpoint inhibitor, pembrolizumab, to platinum-based chemotherapy with paclitaxel and bevacizumab. Additionally, new options for second-line treatment have become available in recent years. Areas covered: Here, we review current investigational drugs and discuss their relative targets, efficacies, and potential within the R/M CC treatment landscape. This review will focus on recently published data and key ongoing clinical trials in patients with R/M CC, covering multiple modes of action, including immunotherapies, antibody-drug conjugates, and tyrosine kinase inhibitors. We searched clinicaltrials.gov for ongoing trials and pubmed.ncbi.nih.gov for recently published trial data, as well as recent years' proceedings from the annual conferences of the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), European Society of Gynaecological Oncology (ESGO), and the International Gynecologic Cancer Society (IGCS). Expert opinion: Therapeutics currently attracting attention include novel immune checkpoint inhibitors, therapeutic vaccinations, antibody-drug conjugates, such as tisotumab vedotin, tyrosine kinase inhibitors targeting HER2, and multitarget synergistic combinations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|